



Ventripoint Issues Option Grants and Reports Exercise of Options

Toronto, Ontario – The Newswire – June 17, 2025 - Ventripoint Diagnostics Ltd. (“**Ventripoint**” or the “**Corporation**”)(TSXV:VPT, OTC:VPTDF) is providing an update on options. On March 12, 2025, the Corporation issued 500,000 option grants at \$0.15 and 500,000 option grants at \$0.20 to contractors to the Corporation. These option grants vested over 4 months and had a term of two years. On June 2, 2025, the Corporation issued 2,000,000 option grants at \$0.10 to employees, consultants and advisors. The option grants vested from immediately to over 3 years and had a term for two to ten years. On June 12, 2025, the Corporation issued 1,635,000 option grants at \$0.10 to employees, consultants and advisors. The option grants vested from immediately to over 3 months and had a term for two years. None of the above option grants were awarded to directors or officers of the Corporation.

Since the last update (see NR February 11, 2024), a total of 3,119,450 options were exercised with a weighted average price of approximately \$0.11 per share for gross proceeds to the Corporation of \$356,385. In addition, 1,994,500 options expired. There are currently 13,100,750 option grants outstanding with exercise prices between \$0.10 to \$0.50 with a weighted average exercise price of \$0.20, and 11,083,250 of these options have vested.

The Corporation has approximately 3.5 million options available for future grants under the Stock Option Plan as approved by shareholders at the last Special and Annual General Meeting of the Corporation. The Corporation has approximately 166 million shares issued and outstanding.

For further information, please contact:

Hugh MacNaught
President and CEO
hmacnaught@ventripoint.com
(604) 671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.



Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.